ATE286534T1 - Modulierung der durch cpg-oligonukleotide verursachten immunstimulierung durch positionsbedingte veränderung von nukleosiden - Google Patents
Modulierung der durch cpg-oligonukleotide verursachten immunstimulierung durch positionsbedingte veränderung von nukleosidenInfo
- Publication number
- ATE286534T1 ATE286534T1 AT00955527T AT00955527T ATE286534T1 AT E286534 T1 ATE286534 T1 AT E286534T1 AT 00955527 T AT00955527 T AT 00955527T AT 00955527 T AT00955527 T AT 00955527T AT E286534 T1 ATE286534 T1 AT E286534T1
- Authority
- AT
- Austria
- Prior art keywords
- nucleosides
- modulation
- cpg oligonucleotides
- positional changes
- stimulation caused
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/18—Type of nucleic acid acting by a non-sequence specific mechanism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14879899P | 1999-08-13 | 1999-08-13 | |
PCT/US2000/022284 WO2001012804A2 (en) | 1999-08-13 | 2000-08-14 | MODULATION OF OLIGONUCLEOTIDE CpG-MEDIATED IMMUNE STIMULATION BY POSITIONAL MODIFICATION OF NUCLEOSIDES |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE286534T1 true ATE286534T1 (de) | 2005-01-15 |
Family
ID=22527436
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT00955527T ATE286534T1 (de) | 1999-08-13 | 2000-08-14 | Modulierung der durch cpg-oligonukleotide verursachten immunstimulierung durch positionsbedingte veränderung von nukleosiden |
Country Status (13)
Country | Link |
---|---|
US (1) | US6476000B1 (de) |
EP (2) | EP1200580B1 (de) |
JP (2) | JP5268214B2 (de) |
KR (1) | KR100651294B1 (de) |
AT (1) | ATE286534T1 (de) |
AU (2) | AU783745B2 (de) |
CA (2) | CA2784789A1 (de) |
DE (1) | DE60017259T2 (de) |
DK (1) | DK1200580T3 (de) |
ES (1) | ES2233426T3 (de) |
MX (1) | MXPA02001610A (de) |
PT (1) | PT1200580E (de) |
WO (1) | WO2001012804A2 (de) |
Families Citing this family (111)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US20030026782A1 (en) | 1995-02-07 | 2003-02-06 | Arthur M. Krieg | Immunomodulatory oligonucleotides |
US20030022854A1 (en) | 1998-06-25 | 2003-01-30 | Dow Steven W. | Vaccines using nucleic acid-lipid complexes |
US6558951B1 (en) * | 1999-02-11 | 2003-05-06 | 3M Innovative Properties Company | Maturation of dendritic cells with immune response modifying compounds |
US6949520B1 (en) | 1999-09-27 | 2005-09-27 | Coley Pharmaceutical Group, Inc. | Methods related to immunostimulatory nucleic acid-induced interferon |
AU5736601A (en) * | 2000-05-01 | 2001-11-12 | Hybridon Inc | Modulation of oligonucleotide cpg-mediated immune stimulation by positional modification of nucleosides |
EP1850850A4 (de) * | 2000-12-08 | 2011-06-15 | 3M Innovative Properties Co | Zusammensetzungen und verfahren zur gezielten verabreichung von immunantwortmodifikatoren |
US7176296B2 (en) | 2001-04-30 | 2007-02-13 | Idera Pharmaceuticals, Inc. | Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides |
US7105495B2 (en) | 2001-04-30 | 2006-09-12 | Idera Pharmaceuticals, Inc. | Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides |
US7785610B2 (en) * | 2001-06-21 | 2010-08-31 | Dynavax Technologies Corporation | Chimeric immunomodulatory compounds and methods of using the same—III |
PT1404873E (pt) | 2001-06-21 | 2013-07-30 | Dynavax Tech Corp | Compostos de imunomodulação quiméricos e métodos de utilização dos mesmos |
WO2003014316A2 (en) * | 2001-08-07 | 2003-02-20 | Dynavax Technologies Corporation | Immunomodulatory compositions, formulations, and methods for use thereof |
US7276489B2 (en) | 2002-10-24 | 2007-10-02 | Idera Pharmaceuticals, Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends |
DK1719511T3 (da) * | 2001-11-16 | 2009-04-14 | Coley Pharm Group Inc | N-[4-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]methansulfonamid, en farmaceutisk sammensætning omfattende samme, og anvendelse deraf |
CA2365732A1 (en) * | 2001-12-20 | 2003-06-20 | Ibm Canada Limited-Ibm Canada Limitee | Testing measurements |
CA2474709A1 (en) | 2002-02-04 | 2003-08-14 | Biomira, Inc. | Immunostimulatory, covalently lipidated oligonucleotides |
BR0307788A (pt) * | 2002-02-22 | 2006-04-04 | 3M Innovative Properties Co | método de redução e tratamento de imunossupressão induzida por uv-b |
CA2388049A1 (en) | 2002-05-30 | 2003-11-30 | Immunotech S.A. | Immunostimulatory oligonucleotides and uses thereof |
NZ538812A (en) | 2002-08-15 | 2009-02-28 | 3M Innovative Properties Co | Immunostimulatory compositions and methods of stimulating an immune response |
AR040996A1 (es) * | 2002-08-19 | 2005-04-27 | Coley Pharm Group Inc | Acidos nucleicos inmunoestimuladores |
WO2004053057A2 (en) * | 2002-12-11 | 2004-06-24 | 3M Innovative Properties Company | Gene expression systems and recombinant cell lines |
JP2006512927A (ja) | 2002-12-11 | 2006-04-20 | コーリー ファーマシューティカル グループ,インコーポレイテッド | 5’cpg核酸およびその使用方法 |
WO2004053452A2 (en) * | 2002-12-11 | 2004-06-24 | 3M Innovative Properties Company | Assays relating to toll-like receptor activity |
PT1575977E (pt) | 2002-12-23 | 2009-12-15 | Dynavax Tech Corp | Oligonucleótidos de sequência imunoestimuladora e métodos de utilização dos mesmos |
US8158768B2 (en) | 2002-12-23 | 2012-04-17 | Dynavax Technologies Corporation | Immunostimulatory sequence oligonucleotides and methods of using the same |
US7387271B2 (en) | 2002-12-30 | 2008-06-17 | 3M Innovative Properties Company | Immunostimulatory combinations |
CA2512484A1 (en) | 2003-01-16 | 2004-05-08 | Hybridon, Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides |
US7354907B2 (en) * | 2003-02-07 | 2008-04-08 | Idera Pharmaceuticals, Inc. | Short immunomodulatory oligonucleotides |
EP1592302A4 (de) * | 2003-02-13 | 2007-04-25 | 3M Innovative Properties Co | Verfahren und zusammensetzungen, die mit irm-verbindungen und dem toll-like rezeptor 8 in zusammenhang stehen |
ATE491463T1 (de) | 2003-02-20 | 2011-01-15 | Univ Connecticut Health Ct | Verfahren zur herstellung von alpha (2) makroglobulin-antigen-molekül-komplexen |
WO2004075865A2 (en) * | 2003-02-27 | 2004-09-10 | 3M Innovative Properties Company | Selective modulation of tlr-mediated biological activity |
KR100681470B1 (ko) * | 2003-03-03 | 2007-02-12 | 연세대학교 산학협력단 | 면역반응 증진용 올리고뉴크레오타이드 |
JP2006519866A (ja) | 2003-03-04 | 2006-08-31 | スリーエム イノベイティブ プロパティズ カンパニー | Uv誘発性の表皮の新形成の予防的治療 |
EP1603510B1 (de) * | 2003-03-13 | 2012-05-09 | 3M Innovative Properties Company | Verfahren zur verbesserung der hautqualität |
JP2006520245A (ja) | 2003-03-13 | 2006-09-07 | スリーエム イノベイティブ プロパティズ カンパニー | 入れ墨の除去方法 |
US20040192585A1 (en) | 2003-03-25 | 2004-09-30 | 3M Innovative Properties Company | Treatment for basal cell carcinoma |
US20040265351A1 (en) * | 2003-04-10 | 2004-12-30 | Miller Richard L. | Methods and compositions for enhancing immune response |
JP2007500210A (ja) * | 2003-04-10 | 2007-01-11 | スリーエム イノベイティブ プロパティズ カンパニー | 金属含有微粒子担体材料を使用した免疫反応調節物質化合物の送達 |
EP1628531A4 (de) | 2003-05-16 | 2010-06-30 | Idera Pharmaceuticals Inc | Synergistische behandlung von krebs durch gemeinsame verwendung von immunomeren und chemotherapeutika |
MXPA06000619A (es) | 2003-07-15 | 2006-04-11 | Hybridon Inc | Estimulacion sinergistica del sistema inmune usando oligonucleotidos inmunoestimuladores y/o compuestos inmunomeros en conjunto con citocinas y/o agentes quimioterapeuticos o terapia de radiacion. |
MXPA06001004A (es) * | 2003-07-31 | 2006-04-27 | 3M Innovative Properties Co | Composiciones para encapsulacion y liberacion controlada. |
CN1852711A (zh) * | 2003-08-05 | 2006-10-25 | 3M创新有限公司 | 使用免疫响应调节化合物的传染病预防 |
WO2005018556A2 (en) | 2003-08-12 | 2005-03-03 | 3M Innovative Properties Company | Hydroxylamine substituted imidazo-containing compounds |
WO2005020912A2 (en) | 2003-08-25 | 2005-03-10 | 3M Innovative Properties Company | Delivery of immune response modifier compounds |
AU2004266162A1 (en) * | 2003-08-25 | 2005-03-03 | 3M Innovative Properties Company | Immunostimulatory combinations and treatments |
EP1658076B1 (de) | 2003-08-27 | 2013-03-06 | 3M Innovative Properties Company | Aryloxy- und arylalkylenoxy-substituierte imidazochinoline |
EP1663222A4 (de) * | 2003-09-02 | 2008-05-21 | 3M Innovative Properties Co | Verfahren im zusammenhang mit der behandlung von schleimhauterkrankungen |
CA2537763A1 (en) * | 2003-09-05 | 2005-03-17 | 3M Innovative Properties Company | Treatment for cd5+ b cell lymphoma |
US7615539B2 (en) | 2003-09-25 | 2009-11-10 | Coley Pharmaceutical Group, Inc. | Nucleic acid-lipophilic conjugates |
US7544697B2 (en) | 2003-10-03 | 2009-06-09 | Coley Pharmaceutical Group, Inc. | Pyrazolopyridines and analogs thereof |
MXPA06003705A (es) | 2003-10-03 | 2006-06-20 | 3M Innovative Properties Co | Imidazoquinolinas sustituidas con alcoxi. |
CN101454451A (zh) | 2003-10-30 | 2009-06-10 | 科勒制药有限公司 | 具有增强免疫刺激能力的c类寡核苷酸类似物 |
CA2543685A1 (en) * | 2003-10-31 | 2005-05-12 | 3M Innovative Properties Company | Neutrophil activation by immune response modifier compounds |
AU2004291122A1 (en) | 2003-11-14 | 2005-06-02 | 3M Innovative Properties Company | Hydroxylamine substituted imidazo ring compounds |
CN1906193A (zh) | 2003-11-14 | 2007-01-31 | 3M创新有限公司 | 肟取代的咪唑环化合物 |
MY161812A (en) | 2003-11-25 | 2017-05-15 | 3M Innovative Properties Co | Substituted imidazo ring systems and methods |
WO2005055932A2 (en) * | 2003-12-02 | 2005-06-23 | 3M Innovative Properties Company | Therapeutic combinations and methods including irm compounds |
US20050226878A1 (en) * | 2003-12-02 | 2005-10-13 | 3M Innovative Properties Company | Therapeutic combinations and methods including IRM compounds |
AU2004304770B2 (en) | 2003-12-08 | 2010-05-06 | Idera Pharmaceuticals, Inc. | Modulation of immunostimulatory properties by small oligonucleotide-based compounds |
US8802853B2 (en) | 2003-12-29 | 2014-08-12 | 3M Innovative Properties Company | Arylalkenyl and arylalkynyl substituted imidazoquinolines |
EP1699398A4 (de) * | 2003-12-30 | 2007-10-17 | 3M Innovative Properties Co | Verbesserung der immunantworten |
WO2005066169A2 (en) | 2003-12-30 | 2005-07-21 | 3M Innovative Properties Company | Imidazoquinolinyl, imidazopyridinyl, and imidazonaphthyridinyl sulfonamides |
TW200612932A (en) | 2004-03-24 | 2006-05-01 | 3M Innovative Properties Co | Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines |
WO2006126981A2 (en) * | 2004-04-28 | 2006-11-30 | 3M Innovative Properties Company | Compositions and methods for mucosal vaccination |
US20050267145A1 (en) * | 2004-05-28 | 2005-12-01 | Merrill Bryon A | Treatment for lung cancer |
US20080154210A1 (en) | 2004-05-28 | 2008-06-26 | Oryxe | Mixture for Transdermal Delivery of Low and High Molecular Weight Compounds |
CA2567789A1 (en) * | 2004-06-08 | 2006-08-03 | Coley Pharmaceutical Gmbh | Abasic oligonucleotide as carrier platform for antigen and immunostimulatory agonist and antagonist |
WO2005123080A2 (en) | 2004-06-15 | 2005-12-29 | 3M Innovative Properties Company | Nitrogen-containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines |
US7897609B2 (en) | 2004-06-18 | 2011-03-01 | 3M Innovative Properties Company | Aryl substituted imidazonaphthyridines |
US7915281B2 (en) | 2004-06-18 | 2011-03-29 | 3M Innovative Properties Company | Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and method |
US8026366B2 (en) | 2004-06-18 | 2011-09-27 | 3M Innovative Properties Company | Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines |
EP1786450A4 (de) * | 2004-08-27 | 2009-11-11 | 3M Innovative Properties Co | Hiv-immunstimulatorische zusammensetzungen |
US20070243215A1 (en) * | 2004-10-08 | 2007-10-18 | Miller Richard L | Adjuvant for Dna Vaccines |
EP1830876B1 (de) | 2004-12-30 | 2015-04-08 | Meda AB | Verwendung von imquimod für die behandlung von hautmetastasen stammend aus einem brustkrebs |
WO2006083440A2 (en) | 2004-12-30 | 2006-08-10 | 3M Innovative Properties Company | Substituted chiral fused [1,2]imidazo[4,5-c] ring compounds |
JP5543068B2 (ja) | 2004-12-30 | 2014-07-09 | スリーエム イノベイティブ プロパティズ カンパニー | キラル縮合[1,2]イミダゾ[4,5−c]環状化合物 |
CA2597092A1 (en) | 2005-02-04 | 2006-08-10 | Coley Pharmaceutical Group, Inc. | Aqueous gel formulations containing immune reponse modifiers |
WO2006086634A2 (en) | 2005-02-11 | 2006-08-17 | Coley Pharmaceutical Group, Inc. | Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods |
AU2006232377A1 (en) | 2005-04-01 | 2006-10-12 | Coley Pharmaceutical Group, Inc. | Pyrazolopyridine-1,4-diamines and analogs thereof |
CA2602590A1 (en) | 2005-04-01 | 2006-10-12 | Coley Pharmaceutical Group, Inc. | 1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases |
CN104278037B (zh) | 2005-10-12 | 2020-09-15 | 艾德拉药物股份有限公司 | 基于变异应答调制Toll样受体的免疫调节寡核苷酸(IRO)化合物 |
US7776834B2 (en) * | 2005-11-07 | 2010-08-17 | Idera Pharmaceuticals, Inc. | Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides |
EP2402442B1 (de) | 2005-11-07 | 2013-07-31 | Idera Pharmaceuticals | Immunostimulatorische Eigenschaften von Oligonukleotid-basierten Verbindungen mit modifizierten immunostimulatorischen Dinukleotiden |
US7470674B2 (en) | 2005-11-07 | 2008-12-30 | Idera Pharmaceuticals, Inc. | Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides |
EP3085373A1 (de) | 2006-02-22 | 2016-10-26 | 3M Innovative Properties Company | Konjugate zur modifizierung von immunreaktionen |
WO2008008432A2 (en) | 2006-07-12 | 2008-01-17 | Coley Pharmaceutical Group, Inc. | Substituted chiral fused( 1,2) imidazo (4,5-c) ring compounds and methods |
MX2009003398A (es) | 2006-09-27 | 2009-08-12 | Coley Pharm Gmbh | Analogos de oligonucleotidos cpg que contienen analogos t hidrofobos con actividad inmunoestimuladora mejorada. |
US20080149123A1 (en) | 2006-12-22 | 2008-06-26 | Mckay William D | Particulate material dispensing hairbrush with combination bristles |
CN101821412A (zh) * | 2007-08-15 | 2010-09-01 | 艾德拉药物股份有限公司 | Toll样受体调控剂 |
US8853177B2 (en) * | 2008-10-06 | 2014-10-07 | Idera Pharmaceuticals, Inc. | Use of inhibitors of toll-like receptors in the prevention and treatment of hypercholesterolemia and hyperlipidemia and diseases related thereto |
WO2011005942A2 (en) * | 2009-07-08 | 2011-01-13 | Idera Pharmaceuticals, Inc. | Oligonucleotide-based compounds as inhibitors of toll-like receptors |
US20110033515A1 (en) * | 2009-08-04 | 2011-02-10 | Rst Implanted Cell Technology | Tissue contacting material |
MX340363B (es) | 2010-11-19 | 2016-07-06 | Idera Pharmaceuticals Inc | Compuestos de oligonucleotidos inmuno-reguladores (iro) que modulan la respuesta inmune basada en receptores tipo toll. |
AU2012261959B2 (en) | 2011-06-03 | 2015-12-03 | Solventum Intellectual Properties Company | Hydrazino 1H-imidazoquinolin-4-amines and conjugates made therefrom |
US9475804B2 (en) | 2011-06-03 | 2016-10-25 | 3M Innovative Properties Company | Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom |
US20130023736A1 (en) | 2011-07-21 | 2013-01-24 | Stanley Dale Harpstead | Systems for drug delivery and monitoring |
WO2015011254A1 (en) | 2013-07-26 | 2015-01-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of bacterial infections |
WO2016180852A1 (en) | 2015-05-12 | 2016-11-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for preparing antigen-specific t cells from an umbilical cord blood sample |
CN108024914A (zh) | 2015-09-17 | 2018-05-11 | Jrx生物技术有限公司 | 改善皮肤的水合作用或润湿作用的方法 |
CN108472358B (zh) * | 2015-09-30 | 2022-06-24 | 盐野义制药株式会社 | 具有免疫赋活活性的核酸衍生物 |
US10940201B2 (en) | 2015-09-30 | 2021-03-09 | Shionogi & Co., Ltd. | Nucleic acid derivative having immunostimulatory activity |
US10526309B2 (en) | 2015-10-02 | 2020-01-07 | The University Of North Carolina At Chapel Hill | Pan-TAM inhibitors and Mer/Axl dual inhibitors |
EP3512499A4 (de) | 2016-09-15 | 2020-08-05 | Idera Pharmaceuticals, Inc. | Immunmodulation mit tlr9-agonisten zur krebsbehandlung |
BR112019019177B8 (pt) * | 2017-03-29 | 2022-09-13 | Shionogi & Co | Composição farmacêutica compreendendo derivados de ácido nucleico tendo atividade imunoestimuladora |
KR20200128116A (ko) | 2018-02-28 | 2020-11-11 | 화이자 인코포레이티드 | Il-15 변이체 및 이의 용도 |
MX2020012539A (es) | 2018-05-23 | 2021-02-16 | Pfizer | Anticuerpos especificos para cd3 y sus usos. |
MX2020012607A (es) | 2018-05-23 | 2021-01-29 | Pfizer | Anticuerpos especificos para gucy2c y sus usos. |
WO2020128893A1 (en) | 2018-12-21 | 2020-06-25 | Pfizer Inc. | Combination treatments of cancer comprising a tlr agonist |
JP7369297B2 (ja) | 2019-12-17 | 2023-10-25 | ファイザー・インク | Cd47、pd-l1に特異的な抗体、およびその使用 |
EP4182346A1 (de) | 2020-07-17 | 2023-05-24 | Pfizer Inc. | Therapeutische antikörper und deren verwendungen |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5149798A (en) | 1989-04-06 | 1992-09-22 | Worcester Foundation For Experimental Biology | Process for synthesizing oligonucleotides and their analogs adaptable to large scale syntheses |
US6153595A (en) * | 1990-08-16 | 2000-11-28 | Isis Pharmaceuticals Inc. | Composition and method for treatment of CMV infections |
JPH06511387A (ja) * | 1991-12-24 | 1994-12-22 | アイシス・ファーマシューティカルス・インコーポレーテッド | β−アミロイド調節のための組成物および方法 |
US6235723B1 (en) * | 1992-03-16 | 2001-05-22 | Isis Pharmaceuticals , Inc. | Antisense oligonucleotide modulation of human protein kinase C-δ expression |
US6207646B1 (en) * | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US5591721A (en) * | 1994-10-25 | 1997-01-07 | Hybridon, Inc. | Method of down-regulating gene expression |
US5968909A (en) * | 1995-08-04 | 1999-10-19 | Hybridon, Inc. | Method of modulating gene expression with reduced immunostimulatory response |
US5652356A (en) * | 1995-08-17 | 1997-07-29 | Hybridon, Inc. | Inverted chimeric and hybrid oligonucleotides |
US5856462A (en) * | 1996-09-10 | 1999-01-05 | Hybridon Incorporated | Oligonucleotides having modified CpG dinucleosides |
US5886165A (en) * | 1996-09-24 | 1999-03-23 | Hybridon, Inc. | Mixed backbone antisense oligonucleotides containing 2'-5'-ribonucleotide- and 3'-5'-deoxyribonucleotides segments |
JP2001514884A (ja) * | 1997-08-19 | 2001-09-18 | ハイブリドン・インク | 新規なhiv特異的合成オリゴヌクレオチド及びその使用方法 |
US6228642B1 (en) * | 1998-10-05 | 2001-05-08 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of tumor necrosis factor-(α) (TNF-α) expression |
-
2000
- 2000-08-14 JP JP2001517689A patent/JP5268214B2/ja not_active Expired - Fee Related
- 2000-08-14 PT PT00955527T patent/PT1200580E/pt unknown
- 2000-08-14 AT AT00955527T patent/ATE286534T1/de active
- 2000-08-14 US US09/639,250 patent/US6476000B1/en not_active Expired - Lifetime
- 2000-08-14 KR KR1020027001695A patent/KR100651294B1/ko not_active IP Right Cessation
- 2000-08-14 WO PCT/US2000/022284 patent/WO2001012804A2/en active IP Right Grant
- 2000-08-14 ES ES00955527T patent/ES2233426T3/es not_active Expired - Lifetime
- 2000-08-14 DK DK00955527T patent/DK1200580T3/da active
- 2000-08-14 CA CA2784789A patent/CA2784789A1/en not_active Abandoned
- 2000-08-14 CA CA002381993A patent/CA2381993A1/en not_active Abandoned
- 2000-08-14 EP EP00955527A patent/EP1200580B1/de not_active Expired - Lifetime
- 2000-08-14 DE DE60017259T patent/DE60017259T2/de not_active Expired - Lifetime
- 2000-08-14 AU AU67720/00A patent/AU783745B2/en not_active Ceased
- 2000-08-14 EP EP10010051A patent/EP2314693A3/de not_active Withdrawn
- 2000-08-14 MX MXPA02001610A patent/MXPA02001610A/es active IP Right Grant
-
2005
- 2005-12-12 AU AU2005242217A patent/AU2005242217A1/en not_active Withdrawn
-
2010
- 2010-09-22 JP JP2010212544A patent/JP2011019527A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP1200580A2 (de) | 2002-05-02 |
CA2381993A1 (en) | 2001-02-22 |
DE60017259D1 (de) | 2005-02-10 |
AU2005242217A1 (en) | 2006-01-12 |
DK1200580T3 (da) | 2005-04-11 |
EP1200580B1 (de) | 2005-01-05 |
US6476000B1 (en) | 2002-11-05 |
WO2001012804A2 (en) | 2001-02-22 |
JP2003526628A (ja) | 2003-09-09 |
KR20020059586A (ko) | 2002-07-13 |
EP2314693A2 (de) | 2011-04-27 |
AU783745B2 (en) | 2005-12-01 |
EP2314693A3 (de) | 2012-11-28 |
AU6772000A (en) | 2001-03-13 |
CA2784789A1 (en) | 2001-02-22 |
DE60017259T2 (de) | 2005-12-08 |
ES2233426T3 (es) | 2005-06-16 |
MXPA02001610A (es) | 2003-07-21 |
JP5268214B2 (ja) | 2013-08-21 |
KR100651294B1 (ko) | 2006-11-28 |
WO2001012804A3 (en) | 2001-09-07 |
JP2011019527A (ja) | 2011-02-03 |
PT1200580E (pt) | 2005-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE286534T1 (de) | Modulierung der durch cpg-oligonukleotide verursachten immunstimulierung durch positionsbedingte veränderung von nukleosiden | |
ATE382690T1 (de) | Modulierung der durch cpg-oligonukleotide verursachte immunstimulierung durch positionsbedingte veränderung von nukleosiden | |
ATE292638T1 (de) | Modulation von oligonukleotid cpg-vermittelter immunstimulation durch modifikation der nucleoside | |
PL375398A1 (en) | Immunostimulatory nucleic acids | |
DK1117672T3 (da) | Antisense-modulation af survivin-ekpression | |
DE60143901D1 (de) | Antisense-modulation der clusterinexpression | |
ATE312202T1 (de) | Menschliche rnase h und entsprechende oligonukleotidverbindungen | |
ATE384072T1 (de) | Modulation der immunostimulatorischen aktivität von immunostimulierenden oligonukleotidanaloga durch positionelle chemische veränderungen | |
EP1131465A4 (de) | Antisense-modulierung der interleukin-15 expression | |
WO2002036743A3 (en) | Antisense modulation of calreticulin expression | |
DE69927495D1 (de) | Verfahren zur regulierung der hematopoiese mit hilfe von cpg oligonukleotide | |
TR200001835T2 (tr) | Aşı. | |
NO20041917L (no) | Spesifikke midler som binder humant angiopoietin-2 | |
DE69403642D1 (de) | 7-deazapurin modifizierte oligonukleotide | |
SG167667A1 (en) | Nucleic acid compositions for stimulating immune responses | |
DE69934998D1 (de) | Antisense modulation der expression von integrin alpha 4 | |
MXPA05008360A (es) | Oligonucleotidos inmunomoduladores cortos. | |
ATE424217T1 (de) | Zusammensetzungen zur steigerung der effizienz von impfstoffen unter verwendung von chemokinen | |
WO2003057847A3 (en) | METHODS AND MATERIALS FOR MODULATING ENaC-BETA | |
EP1448762A4 (de) | Antisense-modulation der expression des toll-ähnlichen rezeptors 4 erfindungsgebiet | |
WO2003040328A3 (en) | Antisense modulation of thyroid hormone receptor interactor 6 expression | |
WO2003040339A3 (en) | Antisense modulation of purinoreceptor p2x¿3? | |
EP1496121A3 (de) | Modulierung der durch CpG-oligonukleotide verursachte Immunstimulierung durch positionsbedingte Veränderung von Nukleosiden | |
WO2003057898A3 (en) | Methods and materials for modulating p2x2 | |
WO2003057846A3 (en) | Methods and materials for modulating task-3 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1200580 Country of ref document: EP |